ScreenerHero

AZN AstraZeneca PLC

NAS · US · Healthcare · Drug Manufacturers - General · astrazeneca.com
156.15USD-7.11%Mkt Cap: 260.71B $P/E: 25.16

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza,…

Industry Peers

Drug Manufacturers - General
Screen all
LLY
Eli Lilly and Company Common Stock
$1.02TUSDP/E 38.4
JNJ
Johnson & Johnson Common Stock
$617.01BUSDP/E 29.7
ABBV
AbbVie Inc. Common Stock
$464.43BUSDP/E 74.2
MRK
Merck & Company, Inc. Common Stock (new)
$356.01BUSDP/E 116.4
RO
Roche Holding AG
$325.55BUSDP/E 23.4
NVS
Novartis AG Common Stock
$268.00BUSDP/E 21.3
NOVN
Novartis AG
$252.68BUSDP/E 22.2
AMGN
Amgen Inc. - Common Stock
$217.90BUSDP/E 25.0
GILD
Gilead Sciences, Inc. - Common Stock
$179.47BUSD
NVO
Novo Nordisk A/S Common Stock
$164.79BUSDP/E 9.4
PFE
Pfizer, Inc. Common Stock
$158.45BUSDP/E 36.6
BMY
Bristol-Myers Squibb Company Common Stock
$124.91BUSDP/E 13.5
SNY
Sanofi - American Depositary Shares
$95.65BUSDP/E 21.8
GSK
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$94.23BUSDP/E 15.1
SAN
Sanofi
$91.14BUSDP/E 21.5
GSK
GSK plc
$76.61BUSDP/E 14.9
BAYN
Bayer Aktiengesellschaft
$46.94BUSD
BIIB
Biogen Inc. - Common Stock
$32.49BUSDP/E 39.1
MRV
Marvell Technology, Inc.
$28.82BUSDP/E 10.3
ORNBV
Orion Oyj Class B
$12.33BUSDP/E 19.3

Key Statistics

Company
Market Cap260.71B USD
Enterprise Value270.81B USD
Revenue (TTM)61.37B USD
Gross Profit48.11B USD
Net Income (TTM)10.22B USD
Revenue/Share39.59 USD
Last Price156.15 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees96.1K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISINGB0009895292
Valuation
P/E (Trailing)25.16
P/E (Forward)13.55
PEG1.10
EV/EBITDA13.61
EV/Revenue4.41
P/S3.97
P/B4.84
EPS (TTM)6.69
EPS (Forward)11.58
52W Range
145.8015% of range212.71
52W High212.71 USD
52W Low145.80 USD
Profitability
Gross Margin81.90%
Oper. Margin23.46%
EBITDA Margin32.44%
Profit Margin17.41%
ROE21.01%
ROA8.96%
Growth
Revenue Growth6.40%
Earnings Growth2.50%
Cash Flow & Leverage
Operating CF14.57B USD
CapEx (TTM)5.91B USD
FCF Margin7.99%
FCF Yield1.88%
Net Debt27.38B USD
Net Debt/EBITDA1.38
Balance Sheet
Debt/Equity0.60
Current Ratio0.89
Quick Ratio0.66
Book Value/Sh32.43 USD
Cash/Share3.20 USD
Dividends
Fwd Div Rate3.20 USD
Trail. Div Rate3.23 USD
Div. Yield2.04%
5Y Avg Yield2.05%
Payout Ratio46.95%
Ex-Div DateAug 7, 2026
Pay DateSep 8, 2026
Splits
Last Split1:2
Split DateFeb 2, 2026
Analyst Consensus
Rating1.5 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)212.17 USD
Upside (mean)+35.9%
Target Range184.00 USD – 240.00 USD
184.00+35.9% to mean240.00
# Analysts11
Ownership
Shares Out.1.55B
Float1.54B
Insiders0.05%
Institutions65.02%
Short Interest
Short Ratio0.7d
Short % Float0.13%
Short % Out.0.13%
Shares Short2.09M
Short (prev mo.)1.89M
Technical
SMA 50163.34 (-4.4%)
SMA 200182.11 (-14.3%)
Beta0.20
S&P 52W Chg14.58%
Avg Vol (30d)4.01M
Avg Vol (10d)2.66M
Technical Indicators
RSI (14)57.3
MACD-0.3776
MACD Signal-1.3138
MACD Hist.+0.9362
BB Upper169.17 USD
BB Middle162.81 USD
BB Lower156.45 USD
BB Width7.81%
ATR (14)3.898 USD
Vol Ratio (20d)0.90x